Usana Health Sciences INC: directors' dealings · United States · SEC (Form 4)

About Usana Health Sciences INC

USANA Health Sciences, Inc. (NYSE: USNA) is a U.S.-based health and wellness company headquartered in Salt Lake City, Utah, United States. Founded in 1992 by Myron W. Wentz, Ph.D., the company develops and manufactures nutritional supplements, functional foods, personal care items, and skincare products, with a long-standing emphasis on science-based preventive health. Historically, USANA built its business through direct selling, using Brand Partners and Preferred Customers as the core of its commercial engine. More recently, the company has broadened its go-to-market mix and now operates across an omni-channel platform that also includes direct-to-consumer, third-party marketplace, and retail channels. USANA reports two business segments: its core nutritional business and Hiya, its direct-to-consumer children’s health platform. The Hiya acquisition, completed in December 2024 with a 78.85% ownership interest, meaningfully expanded USANA’s exposure to the DTC channel and added a differentiated growth layer outside the legacy direct-selling structure. The company also acquired Rise in 2022 and has continued to expand that brand’s product range and distribution footprint over the past three years. Together, these moves indicate a broader strategic effort to diversify revenue sources while leveraging the company’s established nutrition and wellness capabilities. From a competitive standpoint, USANA positions itself around “cellular nutrition,” premium-quality products, and a science-led brand identity. Its international footprint remains an important differentiator: the company operates in 25 geographic markets worldwide, giving it scale and brand reach, while also increasing exposure to foreign exchange volatility and local regulatory complexity. Mainland China is USANA’s largest market and its single largest source of revenue, accounting for about 41.3% of net sales and nearly half of core nutritional active customers in the latest annual report. That concentration creates both opportunity and risk for investors. USANA’s key product lines include Nutritionals and Celavive skincare, alongside products such as CellSentials, BiOmega, HealthPak and Proflavanol. In 2025, the company announced a substantial refresh of its portfolio, including new product launches, reformulations, and upgraded packaging. It also introduced a Health Professional Advisory Council to support product development and credibility in the wellness space. Management has highlighted the new launches and the integration of Hiya as part of a broader growth strategy. Financially, USANA generated approximately $925 million in net sales in fiscal 2025. For investors, the story is one of a mature international health-and-wellness platform that is trying to evolve beyond its historical direct-selling model. The company’s listing on the NYSE in the United States gives it visibility among U.S.-listed consumer health names, but execution risk remains tied to channel transition, product innovation, China exposure, and currency movements.